Inactive Instrument

News Tiger X Medical Inc Other OTC

Equities

US88677A1043

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 27	Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024
Mar. 27	BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	Mar. 27	PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	Mar. 20	AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	Mar. 13	AQ
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	Mar. 13	CI
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	Mar. 12	AQ
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	Mar. 12	CI
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	Mar. 04	AQ
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	Mar. 04	CI
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	Feb. 08	CI
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	Feb. 08	AQ
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	Feb. 08	CI
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	Jan. 31	AQ
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	Jan. 03	AQ
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	Dec. 19	AQ
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	Dec. 19	CI
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes	Dec. 18	AQ
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes	Dec. 18	CI
BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K	Dec. 18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tiger X Medical Inc Other OTC

Equities

US88677A1043

Summary

Filters